CEO of U.S. Rare Disease Treatment Company Sells Millions in Stock After Exercising Stock Options

United Therapeutics Corporation (NASDAQ: UTHR), an American rare-disease therapeutics company, saw its CEO Martine A. Rothblatt exercise 9,500 stock options on May 29, June 1 and June 2, then sell most or all of those shares on the open market at approximately $540–$560 per share. Each of these three transactions generated roughly $5 million—about $15 million in total—equivalent to around ₩20 billion. Following these sales, Rothblatt’s direct holdings dipped slightly to about 40,000 shares. However, when including shares held indirectly through her spouse and family trusts, she still controls more than 640,000 shares. Furthermore, her 10b5-1 trading plan covering roughly 1.7 million stock options (expiring March 2027) remains in effect until the end of 2026.

According to recent SEC filings, Rothblatt has continued to sell additional blocks of 9,500 shares multiple times in June, cashing out about $5 million (roughly ₩7 billion) per transaction—all under her existing 10b5-1 plan. At the same time, United Therapeutics has been rolling out positive pipeline and earnings news: its pulmonary therapy Tyvaso met the primary endpoints in a Phase III trial for idiopathic pulmonary fibrosis, and the company has released its Q1 2026 financial results. (Source: investing.com)

United Therapeutics was founded in 1996 by Martine Rothblatt to develop a treatment for her daughter’s life-threatening pulmonary arterial hypertension. Today, the publicly traded biotech focuses on therapies for pulmonary arterial hypertension and other rare lung diseases, as well as on artificial organs and transplant-alternative technologies such as 3D-printed lungs. Its headquarters are in Silver Spring, Maryland, and Research Triangle Park, North Carolina. The company is also notable for operating under a public benefit corporation structure. (Source: en.wikipedia.org)